Continuous glucose monitoring with multiple daily insulin treatment: Outcome studies

Janet B. McGill, Andrew Ahmann

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Continuous glucose monitoring (CGM) is developing into an increasingly useful tool for glucose monitoring and therapeutic guidance in the treatment of diabetes. Multiple daily doses of insulin (MDI) is the most common method for intensive insulin treatment of type 1 diabetes and is also becoming more common in the treatment of type 2 diabetes as an increasing population with type 2 diabetes experiences progressive beta cell loss. The clinical evidence demonstrating the benefit of CGM in the outcomes of patients treated with MDI is becoming clearer, particularly with the recent completion of several randomized clinical trials addressing both type 1 and 2 diabetes. This evidence is reviewed.

Original languageEnglish (US)
Pages (from-to)S3-S12
JournalDiabetes Technology and Therapeutics
StatePublished - Jun 2017


  • Continuous glucose monitoring
  • Diamond Study
  • Hypoglycemia
  • Multiple daily doses of insulin
  • Type 1 diabetes
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology


Dive into the research topics of 'Continuous glucose monitoring with multiple daily insulin treatment: Outcome studies'. Together they form a unique fingerprint.

Cite this